Tailored by Design: Rethinking the Path to Biosimilar Development
- Thanks to tailored clinical approach of biosimilars development biotech companies can waive costly Phase III comparative efficacy studies when robust analytical and pharmacokinetic similarity to reference products is proven.
- Mabion supports partners in the global biosimilar medicines market. For us analytics is at the core and predictive modelling is on the horizon.

Biosimilars expand access to life-saving biologics. Historically, Comparative Efficacy Studies (CES) were central to demonstrating biosimilar safety and efficacy.
Today, Similarity Assessment Protocols (SAP), supported by advanced analytical methods and extensive product knowledge, provide strong evidence of biosimilarity. As analytical science advances, is routine CES still necessary?
Two Paths, One Goal: From Traditional to Tailored
The EMA proposes a focused, science-driven approach. If analytical similarity, mechanism of action, and pharmacokinetic comparability are established, efficacy may be confirmed without CES. A predefined SAP remains key, emphasizing statistical similarity criteria and proactive decision-making. Rather than lowering standards, this approach strengthens focus on early development.
A regulatory option that, under certain conditions, allows authorisation of biosimilars based on demonstrated comparability at the analytical level with a limited clinical data package streamlines the development process without compromising efficacy and safety.

Tailoring the Path, Keeping the Safeguards
Instead of treating CES as the default, more tailored decision path presented below could be followed. By removing redundant steps, biosimilars can reach patients more quickly and at lower cost. Nevertheless, safeguards remain firmly in place. Those include:
- Proactive similarity assessment protocol
- Tailored, risk-ranked, linked to MoA analytical panel
- Use of orthogonal methods for CQAs and other important attributes
- Predictive and proactive control strategy
- Risk-based justification of any changes
As long as analytical standards are stringent, immunogenicity and safety continue to be assessed, and post-marketing surveillance is performed, safety and efficacy of a biosimilar can be ensured.
The Road Ahead

FAQ
Prepared by:

Analytics Development Division Manager

Specialist of Biological Analytical Methods

Team Leader, Upstream Manager
References
- European Medicines Agency (EMA). Reflection paper on a tailored clinical approach in biosimilar development. EMA/CHMP/BMWP/60916/2025. Draft. Adopted by CHMP: 16 March 2026.
- Tuszyner A. The New Era of Biosimilar Development: Seizing the Opportunity Under EMA’s Streamlined Guidelines. Mabion Science Hub. 2025.
- Guillen E, Barry S, Jost N, Ekman N, Knippel V, Kuhlmann-Gottke J, Maier J, Weise M, Laslop A, Anour R, van Zandbergen G, Kirsch-Stefan N. The Tailored Biosimilar Approach: Expectations and Requirements. Drugs. 2025; 85(5): 601-608.

If you are interested in our services regarding the biosimilar development, please don’t hesitate to contact us. Mabion’s specialist offer individualized approach tailored to the biologic and clinical characteristics of the developed drug. A streamlined biosimilar development path is available as part of our services. We’ll help your drug reach market faster than the competition.


